IVUS CHIP UPP Registry

Objective is to describe in a United States population the clinical efficacy and safety of an IVUS-guided approach in patients who self-identify within a census-defined minority undergoing PCI of complex coronary lesions, as well as clinical outcomes up to 2 years.

Inclusion criteria

• The patient must be ≥18 years of age and self-identify within a US census-defined minority
• Patients with an indication for PCI of at least one lesion satisfying any of the following criteria:

• Angiographic heavy calcification
• Ostial lesions
• True bifurcation lesions involving side-branches >2.5mm
• Left main lesions
• Chronic total occlusion
• In-stent restenosis
• Long-lesions (estimated stent length > 28mm) OR Patient with an indication for PCI for any lesion and in need for elective mechanical circulatory support assisted PCI
• Presenting with silent ischemia, stable angina, unstable angina or non-ST-elevation acute coronary syndrome (NSTE-ACS)
• All lesions must be suitable for treatment with FDA-approved contemporary generation drug eluting stents or drug-coated balloons
• The patient is willing and able to cooperate with registry procedures and follow-up until registry completion
• Subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she (or an authorized legal representative) provides informed consent prior to any protocol-related procedure, as approved by the appropriate IRB

Exclusion criteria

• ST-elevation myocardial infarction or cardiogenic shock within prior 7 days
• Known untreated severe valvular heart disease
• Contraindication on the use of IVUS (i.e. extreme vessel tortuosity)
• Requiring PCI in a diseased aorto-coronary bypass
• Known contraindication or hypersensitivity to anticoagulants
• Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors
• Non-cardiac co-morbidities with a life expectancy less than 1 year
• A patients that is currently participating in a clinical trial that has not yet reached its primary endpoint cannot be included in this registry. A patient may only be enrolled in this registry once.